Spaces:
Sleeping
Sleeping
Download classes_of_ddis.csv from d142111015/DiabeTAPP: direct link, hf CLI and curl.
- Browser
- Download file 5.31 kB
-
https://huggingface.co/spaces/d142111015/DiabeTAPP/resolve/main/classes_of_ddis.csv
- Command line
-
hf download hf://spaces/d142111015/DiabeTAPP/classes_of_ddis.csv
-
curl -L -o classes_of_ddis.csv https://huggingface.co/spaces/d142111015/DiabeTAPP/resolve/main/classes_of_ddis.csv
5.31 kB
| class,DDI | |
| 0,The excretion of drug_a can be decreased when combined with drug_b. | |
| 1,The excretion of drug_a can be increased when combined with drug_b. | |
| 2,The excretion of drug_b can be decreased when combined with drug_a. | |
| 3,The metabolism of drug_a can be decreased when combined with drug_b. | |
| 4,The metabolism of drug_a can be increased when combined with drug_b. | |
| 5,The metabolism of drug_b can be decreased when combined with drug_a. | |
| 6,The metabolism of drug_b can be increased when combined with drug_a. | |
| 7,The protein binding of drug_a can be decreased when combined with drug_b. | |
| 8,The risk or severity of Cardiac Arrhythmia can be increased when drug_b is combined with drug_a. | |
| 9,The risk or severity of adverse effects can be increased when drug_a is combined with drug_b. | |
| 10,The risk or severity of adverse effects can be increased when drug_b is combined with drug_a. | |
| 11,The risk or severity of angioedema can be increased when drug_a is combined with drug_b. | |
| 12,The risk or severity of angioedema can be increased when drug_b is combined with drug_a. | |
| 13,The risk or severity of bleeding can be increased when drug_a is combined with drug_b. | |
| 14,The risk or severity of hyperglycemia can be increased when drug_b is combined with drug_a. | |
| 15,The risk or severity of hyperkalemia can be increased when drug_a is combined with drug_b. | |
| 16,The risk or severity of hyperkalemia can be increased when drug_b is combined with drug_a. | |
| 17,The risk or severity of hypoglycemia can be increased when drug_a is combined with drug_b. | |
| 18,The risk or severity of hypoglycemia can be increased when drug_b is combined with drug_a. | |
| 19,The risk or severity of hypotension and orthostatic hypotension can be increased when drug_a is combined with drug_b. | |
| 20,The risk or severity of hypotension can be increased when drug_a is combined with drug_b. | |
| 21,The risk or severity of hypotension can be increased when drug_b is combined with drug_a. | |
| 22,"The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when drug_a is combined with drug_b." | |
| 23,The risk or severity of lactic acidosis can be increased when drug_b is combined with drug_a. | |
| 24,The risk or severity of liver damage can be increased when drug_a is combined with drug_b. | |
| 25,The risk or severity of myopathy and rhabdomyolysis can be increased when drug_b is combined with drug_a. | |
| 26,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when drug_a is combined with drug_b." | |
| 27,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when drug_b is combined with drug_a." | |
| 28,The risk or severity of neutropenia can be increased when drug_a is combined with drug_b. | |
| 29,The risk or severity of orthostatic hypotension and syncope can be increased when drug_a is combined with drug_b. | |
| 30,"The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when drug_a is combined with drug_b." | |
| 31,The risk or severity of rhabdomyolysis can be increased when drug_b is combined with drug_a. | |
| 32,The risk or severity of thrombocytopenia can be increased when drug_a is combined with drug_b. | |
| 33,The risk or severity of weight gain and edema formation can be increased when drug_b is combined with drug_a. | |
| 34,The serum concentration of drug_a can be decreased when it is combined with drug_b. | |
| 35,The serum concentration of drug_a can be increased when it is combined with drug_b. | |
| 36,The serum concentration of drug_b can be decreased when it is combined with drug_a. | |
| 37,The serum concentration of drug_b can be increased when it is combined with drug_a. | |
| 38,The therapeutic efficacy of drug_a can be decreased when used in combination with drug_b. | |
| 39,The therapeutic efficacy of drug_a can be increased when used in combination with drug_b. | |
| 40,The therapeutic efficacy of drug_b can be increased when used in combination with drug_a. | |
| 41,drug_a may decrease the excretion rate of drug_b which could result in a higher serum level. | |
| 42,drug_a may increase the QTc-prolonging activities of drug_b. | |
| 43,drug_a may increase the anticoagulant activities of drug_b. | |
| 44,drug_a may increase the diuretic activities of drug_b. | |
| 45,drug_a may increase the excretion rate of drug_b which could result in a lower serum level and potentially a reduction in efficacy. | |
| 46,drug_a may increase the hepatotoxic activities of drug_b. | |
| 47,drug_a may increase the hypoglycemic activities of drug_b. | |
| 48,drug_a may increase the hypolipidaemic activities of drug_b. | |
| 49,drug_a may increase the hypotensive activities of drug_b. | |
| 50,drug_a may increase the vasodilatory activities of drug_b. | |
| 51,drug_b may decrease the excretion rate of drug_a which could result in a higher serum level. | |
| 52,drug_b may decrease the hypoglycemic activities of drug_a. | |
| 53,drug_b may increase the diuretic activities of drug_a. | |
| 54,drug_b may increase the excretion rate of drug_a which could result in a lower serum level and potentially a reduction in efficacy. | |
| 55,drug_b may increase the hypoglycemic activities of drug_a. | |
| 56,drug_b may increase the hypolipidaemic activities of drug_a. | |
| 57,drug_b may increase the hypotensive activities of drug_a. | |
| 58,drug_b may increase the myopathic rhabdomyolysis activities of drug_a. | |
| 59,drug_b may increase the orthostatic hypotensive activities of drug_a. | |